2 recruiting, 2 withdrawn, 1 completed, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Withdrawn 2, Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow High Grade Sarcoma: new trials by email Literature Review of High Grade Sarcoma trials Research Report on High Grade Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial Electronic Health Record Review, Fluorescence Imaging, Fluorescence-Guided Surgery - High Grade Sarcoma, Sarcoma | Phase 2 | Recruiting | City of Hope Medical Center | 22 | 2026-08-14 | 2026-10-16 |
| Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma Intensity Modulated Radiation Therapy (IMRT), MRI - High Grade Sarcoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2022-05-18 | 2025-12-04 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Anlotinib Hydrochloride, Placebo Oral Tablet - Soft Tissue Sarcoma Adult, High Grade Sarcoma | Phase 2 | Completed | Fudan University | 88 | 2019-05-13 | 2025-05-14 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
Dermatofibrosarcoma (3) · Histiocytoma, Malignant Fibrous (3) · Leiomyosarcoma (3) · Sarcoma (3) · Sarcoma, Synovial (3) · Bone Neoplasms (2) · Hemangiosarcoma (2) · Liposarcoma (2) · Rhabdomyosarcoma (2) · Neurofibrosarcoma (1) · Osteosarcoma (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Fibrosarcoma (3) · Histiocytoma (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Fibrous Tissue (3) · Neoplasms, Muscle Tissue (3) · Bone Diseases (2) · Musculoskeletal Diseases (2) · Myosarcoma (2) · Neoplasms by Site (2) · Neoplasms, Adipose Tissue (2) · Neoplasms, Vascular Tissue (2) · Neoplasms, Bone Tissue (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Gemcitabine (2) · Indocyanine Green (1) · Optical Imaging (1) · Radiotherapy, Intensity-Modulated (1) · pazopanib (1) · sapanisertib (1)
Brown University (2) · City of Hope Medical Center (1) · Fudan University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1)
United States (5) · China (1)
Arash O Naghavi, MD, MS (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Don S Dizon, MD (1) · Galina G Lagos, MD (1) · Thinzar Lwin (1) · Wangjun Yan (1) · William D Tap (1)
P30CA033572 (1), U10CA180821 (1)